DSK Legal Advised HealthQuad Fund-II on USD 13 Million Investment in Beta Drugs

DSK Legal Advised HealthQuad Fund-II on USD 13 Million Investment in Beta Drugs

DSK Legal represented and advised HealthQuad Fund-II in its USD 13 million (approximately INR 117 crore) investment in Beta Drugs Limited, a listed entity. The investment was made through the subscription of equity shares and compulsory convertible debentures.

Other investors participating in this funding round included Inti Capital VCC Inti Capital I ("Inti Capital") and Generational Capital Breakout Fund 1. Beta Drugs is engaged in the manufacturing, distribution, and sale of pharmaceutical products across domestic and international markets, specialising in oncology-focused formulations.

The scope of work of DSK Legal included:

i. reviewing, revising, negotiating and finalizing the share subscription agreement, shareholders agreement and other transaction related documents; and
ii. advising on SEBI related compliances; and
iii. assisting in the execution and closing of the transaction.

DSK Legal Team included Partner Nakul Batra, Principal Associate Palak Sehgal, Senior Associate Devbrat Singh, Associate Aankhi Anwesha and Associate Daksh Krishnan.

Click to Know more about DSK Legal